, showing a decrease of Baht 55.30 million or representing 24.14 % decrease since there have been only 5 ongoing projects whereas a subsidiary had 1 additional ongoing project with its contract value of Baht

849.62 Increase(Decrease) (2.39) 65.91 4.62 74.26 142.40 Compared revenue for 6 months (Million Baht) 3 of 8 Operating results classified by business are as follows: Management service business Revenue

Increase (Decrease) % Change Sales income 15,400.82 15,097.66 303.16 2.01% Rental and service income 493.36 480.81 12.55 2.61% Other income 599.77 577.93 21.84 3.78% Total revenues 16,493.95 16,156.40 337.56

year, mostly from revenue from UAC which increased Baht 977.69 million, which resulted in the increase in gross profit of Baht 20.62 million and the decrease in gross profit margin for 9-month period of

17.74% 20.03 9.21% 49.42 246.73% Jul – Sep 63 Jul – Sep 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขที่ 111 หมู่ที่ 2 ตาํบลท่าจนี อาํเภอเมืองสมุทรสาคร จงัหวดัสมุทรสาคร 74000 111 Moo 2

and its subsidiary for the third quarter ended September 30, 2019 which the details are as follows: Unit: million Baht For 3-month period (July-Sep) 2019 2018 Change % Increase (Decrease) Revenue from

in Q1-2023. Total operating expenses in Q2-2023 have changed in the same direction and at a similar rate with the increase and decrease in revenue when compared to Q1- 2023 and Q2- 2022. However, the

year 2018 to reduce capital burden and expenditure of the company to be at an appropriate level and be ready to focus on a strong core business operation to create growth in the future. 6 (4) Details of

allotment as follows: 1. Capital Decrease and Increase Capital Decrease The Board of Directors Meeting has passed a resolution to approve the decrease of the Company’s registered capital amounting to Baht

the resolution of Board of Directors Meeting No. 4/2019, held on 29 March 2019 in respect of a capital increase and share allotment as follows: 1. Capital Decrease and Increase Capital Decrease The